Characteristics and treatment of the 72 patients achieving complete remission and having MRD assessed in the PETHEMA phase 3 FLUGAZA clinical trial
| Characteristic . | Value . |
|---|---|
| Age at diagnosis, y | |
| Median | 73 |
| Range | 65-87 |
| White cell count (×103/μL) at diagnosis, no. (%) | |
| <100 | 48 (67) |
| ≥100 | 24 (33) |
| Risk group, no. (%) | |
| Favorable | 15 (21) |
| Intermediate | 13 (18) |
| Adverse | 39 (54) |
| Missing | 5 (7) |
| Treatment, no. (%) | |
| FLUGA | 36 (50) |
| AZA | 36 (50) |
| Median follow-up | |
| Median | 31 |
| Range | 7-58 |
| Characteristic . | Value . |
|---|---|
| Age at diagnosis, y | |
| Median | 73 |
| Range | 65-87 |
| White cell count (×103/μL) at diagnosis, no. (%) | |
| <100 | 48 (67) |
| ≥100 | 24 (33) |
| Risk group, no. (%) | |
| Favorable | 15 (21) |
| Intermediate | 13 (18) |
| Adverse | 39 (54) |
| Missing | 5 (7) |
| Treatment, no. (%) | |
| FLUGA | 36 (50) |
| AZA | 36 (50) |
| Median follow-up | |
| Median | 31 |
| Range | 7-58 |